Cardiac Myosin Activation in the Treatment of Congestive Heart Failure: New Therapeutic Options and Review of Literature

Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlight the cardiac myosin activator class of drugs and the trials to date highlighting their effects on HF outcomes.

Automated summary

This article highlights a newer class of medications targeting reduced myocardial contractility in congestive heart failure (HF), despite ongoing morbidity and mortality associated with the condition. Trials have shown promising effects on HF outcomes, emphasizing the potential for improved therapeutic options.